R. Rosell, E. Carcereny, R. Gervais, A. Vergnenegre, B. Massuti et al., Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive nonsmall-cell lung cancer (EURTAC): A multicenter, open-label.; randomised phase 3 trial, Lancet Oncol, vol.13, pp.239-246, 2012.

B. J. Solomon, T. Mok, D. W. Kim, Y. L. Wu, K. Nakagawa et al., First-line crizotinib versus chemotherapy in ALK-positive lung cancer, N. Engl. J. Med, vol.371, pp.2167-2177, 2014.

F. De-fraipont, G. Levallet, C. Creveuil, E. Bergot, M. Beau-faller et al., Intergroupe Francophone de Cancérologie Thoracique. An apoptosis methylation prognostic signature for early lung cancer in the IFCT-0002 trial, Clin. Cancer Res, vol.18, pp.2976-2986, 2012.

F. Dubois, M. Keller, O. Calvayrac, F. Soncin, L. Hoa et al., RASSF1A Suppresses the Invasion and Metastatic Potential of Human Non-Small Cell Lung Cancer Cells by Inhibiting YAP Activation through the GEF-H1/RhoB Pathway, Cancer Res, vol.76, pp.1627-1640, 2016.
URL : https://hal.archives-ouvertes.fr/hal-02037182

M. Keller, F. Dubois, S. Teulier, A. P. Martin, J. Levallet et al., NDR2 kinase contributes to cell invasion and cytokinesis defects induced by the inactivation of RASSF1A tumor-suppressor gene in lung cancer cells, J. Exp. Clin. Cancer Res, vol.38, pp.158-171, 2019.
URL : https://hal.archives-ouvertes.fr/hal-02086738

S. Noble, K. L. Goa, and . Gemcitabine, A review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer, Drugs, vol.54, pp.447-472, 1997.

B. A. Weaver, How Taxol/paclitaxel kills cancer cells, Mol. Biol. Cell, vol.25, pp.2677-2681, 2014.

L. Chevalier, T. Scagliotti, G. Natale, R. Danson, S. Rosell et al., Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: A meta-analysis of sur vival outcomes, Lung Cancer, vol.47, pp.69-80, 2005.

S. Ramalingam and C. P. Belani, Paclitaxel for non-small cell lung cancer, Expert Opin. Pharmacother, vol.5, pp.1771-1780, 2004.

D. Matallanas, D. Romano, K. Yee, K. Meissl, L. Kucerova et al., RASSF1A elicits apoptosis through an MST2 pathway directing proapoptotic transcription by the p73 tumor suppressor protein, Mol. Cell, vol.27, pp.962-975, 2007.

A. M. Richter, G. P. Pfeifer, and R. H. Dammann, The RASSFproteins in cancer; from epigenetic silencing to functional characterization, Biochim. Biophys. Acta, vol.1796, pp.114-128, 2009.

C. Guo, X. Zhang, and G. P. Pfeifer, The tumor suppressor RASSF1A prevents dephosphorylation of the mammalian STE20-like kinases MST1 and MST2, J. Biol. Chem, vol.286, pp.6253-6261, 2011.

J. Dong, G. Feldmann, J. Huang, S. Wu, N. Zhang et al., Elucidation of a universal size-control mechanism in Drosophila and mammals, Cell, vol.130, pp.1120-1133, 2007.

D. L. Vaux, J. Silke, and . Iaps, RINGs and ubiquitylation, Nat. Rev. Mol. Cell Biol, vol.6, pp.287-297, 2005.

F. Hu, D. Pan, W. Zheng, T. Yan, X. He et al., Elucidating respective functions of two domains BIR and C-helix of human IAP survivin for precise targeted regulating mitotic cycle.; apoptosis and autophagy of cancer cells, Oncotarget, vol.8, pp.113687-113700, 2017.

L. Xu, J. Zhu, X. Hu, H. Zhu, H. T. Kim et al., c-IAP1 cooperates with Myc by acting as a ubiquitin ligase for Mad1, Mol. Cell, vol.28, pp.914-922, 2007.

T. Dogan, G. S. Harms, M. Hekman, C. Karreman, T. K. Oberoi et al., X-linked and cellular IAPs modulate the stability of C-RAF kinase and cell motility, Nat. Cell Biol, vol.10, pp.1447-1455, 2008.

J. Cartier, J. Berthelet, A. Marivin, S. Gemble, V. Edmond et al., Cellular inhibitor of apoptosis protein-1 (cIAP1) can regulate E2F1 transcription factor-mediated control of cyclin transcription, J. Biol. Chem, vol.286, pp.26406-26417, 2011.
URL : https://hal.archives-ouvertes.fr/inserm-02337357

S. Fulda, Regulation of cell migration, invasion and metastasis by IAP proteins and their antagonists, Oncogene, vol.33, pp.671-686, 2014.

L. Dubrez and K. Rajalingam, IAPs and cell migration, Semin. Cell Dev. Biol, vol.39, pp.124-131, 2015.

J. Ekedahl, B. Joseph, M. Y. Grigoriev, M. Müller, C. Magnusson et al., Expression of Inhibitor of Apoptosis Proteins in Small-and Non-Small-Cell Lung Carcinoma Cells, Exp. Cell Res, vol.279, pp.277-290, 2002.

A. M. Hunter, E. C. Lacasse, and R. G. Korneluk, The inhibitors of apoptosis (IAPs) as cancer targets, Apoptosis, vol.12, pp.1543-1568, 2007.

S. T. Beug, H. H. Cheung, E. C. Lacasse, and R. G. Korneluk, Modulation of immune signalling by inhibitors of apoptosis, Trends Immunol, vol.33, pp.535-545, 2012.

A. B. Pilling, O. Hwang, A. Boudreault, A. Laurent, and C. Hwang, IAP Antagonists Enhance Apoptotic Response to Enzalutamide in Castration-Resistant Prostate Cancer Cells via Autocrine TNF-? Signaling, Prostate, vol.77, pp.866-877, 2017.

M. Sato, J. E. Larsen, W. Lee, H. Sun, D. S. Shames et al., Human lung epithelial cells progressed to malignancy through specific oncogenic manipulations, Mol. Cancer Res, vol.11, pp.638-650, 2013.

D. G. Burbee, E. Forgacs, S. Zöchbauer-müller, L. Shivakumar, K. Fong et al., Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression, J. Natl. Cancer Inst, vol.93, pp.691-709, 2001.

W. Wen, F. Zhu, J. Zhang, Y. S. Keum, T. Zykova et al., MST1 promotes apoptosis through phosphorylation of histone H2AX, J. Biol. Chem, vol.285, pp.39108-39116, 2010.

F. Dubois, B. Jean-jacques, H. Roberge, M. Bénard, L. Galas et al., A role for RASSF1A in tunneling nanotube formation between cells through GEFH1/Rab11 pathway control, Cell Commun. Signal, vol.16, pp.66-76, 2018.
URL : https://hal.archives-ouvertes.fr/hal-02010920

E. Bandala, M. Espinosa, V. Maldonado, and J. Meléndez-zajgla, Inhibitor of apoptosis-1 (IAP-1) expression and apoptosis in non-small-cell lung cancer cells exposed to gemcitabine, Biochem. Pharmacol, vol.1, pp.13-19, 2001.

C. Yang, H. Wang, B. Zhang, Y. Chen, Y. Zhang et al., LCL161 increases paclitaxel-induced apoptosis by degrading cIAP1 and cIAP2 in NSCLC, J. Exp. Clin. Cancer Res, vol.35, pp.158-170, 2016.

T. Samuel, K. Okada, M. Hyer, K. Welsh, J. M. Zapata et al., cIAP1 Localizes to the nuclear compartment and modulates the cell cycle, Cancer Res, vol.65, pp.210-218, 2005.

M. E. Reeves, M. Firek, S. T. Chen, and Y. Amaar, The RASSF1 Gene and the Opposing Effects of the RASSF1A and RASSF1C Isoforms on Cell Proliferation and Apoptosis, Mol. Biol. Int, 2013.

D. Schaeffer, J. A. Somarelli, G. Hanna, G. M. Palmer, and M. A. Garcia-blanco, Cellular migration and invasion uncoupled: Increased migration is not an inexorableconsequence of epithelial-to mesenchymal transition, Mol. Cell Biol, vol.34, pp.3486-3499, 2014.

N. S. Kenneth and C. S. Duckett, IAP proteins: Regulators of cell migration and development, Curr. Opin. Cell Biol, vol.24, pp.871-885, 2012.

T. K. Oberoi-khanuja, A. Murali, and K. Rajalingam, IAPs on the move: Role of inhibitors of apoptosis proteins in cell migration, Cell Death Dis, vol.4, pp.784-799, 2013.

A. Dallol, A. Agathanggelou, S. Tommasi, G. P. Pfeifer, E. R. Maher et al., Involvement of the RASSF1A tumor suppressor gene in controlling cell migration, Cancer Res, vol.65, pp.7653-7659, 2005.

L. M. Liu, S. Tommasi, D. H. Lee, R. Dammann, and G. Pfeifer, Control of microtubule stability by the RASSF1A tumor suppressor, Oncogene, vol.22, pp.8125-8136, 2003.

A. Dallol, A. Agathanggelou, S. L. Fenton, J. Ahmed-choudhury, L. Hesson et al., RASSFIA interacts with microtubule-associated proteins and modulates microtubule dynamics, Cancer Res, vol.64, pp.4112-4116, 2004.

H. Xiao, P. Verdier-pinard, N. Fernandez-fuentes, B. Burd, R. Angeletti et al., Insights into the mechanism of microtubule stabilization by Taxol, Proc. Natl. Acad. Sci, vol.103, pp.10166-10173, 2006.

S. H. Kaufmann and W. C. Earnshaw, Induction of apoptosis by cancer chemotherapy, Exp. Cell Res, vol.256, pp.42-49, 2000.

H. Donninger, M. L. Schmidt, J. Mezzanotte, T. Barnoud, and G. J. Clark, Ras signaling through RASSF proteins, Semin. Cell Dev. Biol, vol.58, pp.86-95, 2016.

D. W. Nicholson, A. Ali, N. A. Thornberry, J. P. Vaillancourt, C. K. Ding et al., Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis, Nature, vol.376, pp.37-43, 1995.

S. Baksh, S. Tommasi, S. Fenton, V. C. Yu, L. M. Martins et al., The tumor suppressor RASSF1A and MAP-1 link death receptor signaling to Bax conformational change and cell death, Mol. Cell, vol.18, pp.637-650, 2005.

M. D. Vos, A. Dallol, K. Eckfeld, N. P. Allen, H. Donninger et al., The RASSF1A tumor suppressor activates Bax via MOAP-1, J. Biol. Chem, vol.281, pp.4557-4563, 2006.

C. J. Foley, H. Freedman, S. L. Choo, C. Onyskiw, N. Y. Fu et al., Dynamics of RASSF1A/MOAP-1 association with death receptors, Mol. Cell Biol, vol.28, pp.4520-4535, 2008.

L. Fu and S. Zhang, RASSF1A promotes apoptosis and suppresses the proliferation of ovarian cancer cells, Int. J. Mol. Med, vol.33, pp.1153-1160, 2014.

A. W. Whitehurst, R. Ram, L. Shivakumar, B. Gao, J. D. Minna et al., The RASSF1A tumor suppressor restrains anaphase-promoting complex/cyclosome activity during the G1/S phase transition to promote cell cycle progression in human epithelial cells, Mol. Cell Biol, vol.28, pp.3190-3197, 2008.

K. H. Lu, K. H. Lue, M. C. Chou, and J. G. Chung, Paclitaxel induces apoptosis via caspase-3 activation in human osteogenic sarcoma cells (U-2 OS), J. Orthop. Res, vol.23, pp.988-994, 2005.

M. L. Flores, C. Castilla, R. Ávila, M. Ruiz-borrego, C. Sáez et al., Paclitaxel sensitivity of breast cancer cells requires efficient mitotic arrest and disruption of Bcl-xL/Bak interaction, Breast Cancer Res. Treat, vol.133, pp.917-928, 2012.

M. Jelínek, K. Balu?íková, M. Schmiedlová, V. N?mcová-fürstová, J. ?rámek et al., The role of individual caspases in cell death induction by taxanes in breast cancer cells, Cancer Cell Int, vol.15, pp.8-17, 2015.

Y. Wang, Y. Kuramitsu, K. Tokuda, B. Baron, T. Kitagawa et al., Gemcitabine induces poly (ADP-ribose) polymerase-1 (PARP-1) degradation through autophagy in pancreatic cancer, PLoS ONE, vol.9, p.109076, 2014.

D. A. Jacob, M. Bahra, J. M. Langrehr, S. Boas-knoop, R. Stefaniak et al., Combination therapy of poly(ADP-ribose) polymerase inhibitor 3-aminobenzamide and gemcitabine shows strong antitumor activity in pancreatic cancer cells, J. Gastroenterol. Hepatol, vol.22, pp.738-748, 2007.

K. Hastak, E. Alli, and J. M. Ford, Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-Ribose) polymerase inhibition gemcitabine.; and cisplatin, Cancer Res, vol.70, pp.7970-7980, 2010.

W. Song, L. Tang, Y. Xu, J. Xu, W. Zhang et al., PARP inhibitor increases chemosensitivity by upregulating miR-664b-5p in BRCA1-mutated triple-negative breast cancer, vol.7, pp.42319-42332, 2017.

S. Kassler, H. Donninger, M. J. Birrer, and G. J. Clark, RASSF1A and the Taxol Response in Ovarian Cancer, Mol. Biol. Int, pp.263267-263283, 2012.

J. L. Koff, S. Ramachandiran, and L. Bernal-mizrachi, A time to kill: Targeting apoptosis in cancer, Int. J. Mol. Sci, vol.16, pp.2942-2955, 2015.

L. Zender, M. S. Spector, W. Xue, P. Flemming, C. Cordon-cardo et al., Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach, Cell, vol.125, pp.1253-1267, 2006.

R. Colnaghi, C. M. Connell, R. M. Barrett, and S. P. Wheatley, Separating the anti-apoptotic and mitotic roles of survivin, J. Biol. Chem, vol.281, pp.33450-33466, 2006.

J. R. Aspe, C. J. Diaz-osterman, J. M. Jutzy, S. Deshields, S. Whang et al., Enhancement of Gemcitabine sensitivity in pancreatic adenocarcinoma by novel exosome-mediated delivery of the Survivin-T34A mutant, J. Extracell. Vesicles, vol.17, pp.3-24, 2014.

S. Mehrotra, L. R. Languino, C. M. Raskett, A. M. Mercurio, T. Dohi et al., IAP regulation of metastasis, Cancer Cell, vol.17, pp.53-64, 2010.

R. Xie, S. Nguyen, K. Mckeehan, F. Wang, W. L. Mckeehan et al., Microtubule-associated protein 1s (MAP1S) bridges autophagic components with microtubules and mitochondria to affect autophagosomal biogenesis and degradation, J. Biol. Chem, vol.286, pp.10367-10377, 2011.

M. El-kalla, C. Onyskiw, and S. Baksh, Functional importance of RASSF1A microtubule localization and polymorphisms, Oncogene, vol.29, pp.5729-5740, 2010.

L. Liu, A. Vo, and W. L. Mckeehan, Specificity of the methylation-suppressed A isoform of candidate tumor suppressor RASSF1 for microtubule hyperstabilization is determined by cell death inducer C19ORF5, Cancer Res, vol.65, pp.1830-1838, 2005.

K. Sun, X. H. Tang, and Y. K. Xie, Paclitaxel combined with harmine inhibits the migration and invasion of gastric cancer cells through downregulation of cyclooxygenase-2 expression, Oncol. Lett, vol.10, pp.1649-1654, 2015.

H. Zou, L. Li, I. Garcia-carcedo, Z. P. Xu, M. Monteiro et al., Synergistic inhibition of colon cancer cell growth with nanoemulsion-loaded paclitaxel and PI3K/mTOR dual inhibitor BEZ235 through apoptosis, Int. J. Nanomed, vol.11, pp.1947-1958, 2016.

I. A. Ismail, G. H. El-sokkary, and S. H. Saber, Low doses of Paclitaxel repress breast cancer invasion through DJ-1/KLF17 signalling pathway, Clin. Exp. Pharmacol. Physiol, pp.27-40, 2018.

H. Kajiyama, K. Shibata, M. Terauchi, M. Yamashita, K. Ino et al., Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells, Int. J. Oncol, vol.31, pp.277-283, 2007.

C. H. Cheung, H. H. Chen, C. C. Kuo, C. Y. Chang, M. S. Coumar et al., Survivin counteracts the therapeutic effect of microtubule de-stabilizers by stabilizing tubulin polymers, Mol. Cancer, vol.3, pp.8-43, 2009.

V. Westeel, E. Quoix, M. Puyraveau, A. Lavolé, D. Braun et al., A randomised trial comparing preoperative to perioperative chemotherapy in earlystage non-small-cell lung cancer (IFCT 0002 trial), Eur. J. Cancer, vol.49, pp.2654-2664, 2013.

G. Levallet, E. Bergot, M. Antoine, C. Creveuil, A. O. Santos et al., High TUBB3 expression.; an independent prognostic marker in patients with early non-small cell lung cancer treated by preoperative chemotherapy.; is regulated by K-Ras signaling pathway, Mol. Cancer Ther, vol.11, pp.1203-1213, 2012.
URL : https://hal.archives-ouvertes.fr/hal-00718843

A. N. Takeda, T. K. Oberoi-khanuja, G. Glatz, K. Schulenburg, R. P. Scholz et al., Ubiquitin-dependent regulation of MEKK2/3-MEK5-ERK5 signaling module by XIAP and cIAP1, EMBO J, vol.33, pp.1784-1801, 2014.

H. S. Jin and T. H. Lee, Cell cycle-dependent expression of cIAP2 at G2/M phase contributes to survival during mitotic cell cycle arrest, Biochem. J, vol.399, pp.335-342, 2006.

S. L. Petersen, M. Peyton, J. D. Minna, and X. Wang, Overcoming cancer cell resistance to Smac mimetic induced apoptosis by modulating cIAP-2 expression, Proc. Natl. Acad. Sci, vol.107, pp.11936-11941, 2010.

G. Levallet, F. Dubois, P. Fouret, M. Antoine, S. Brosseau et al., MSH2/BRCA1 expression as a DNA-repair signature predicting survival in early-stage lung cancer patients from the IFCT-0002 Phase 3 Trial, Oncotarget, vol.8, pp.4313-4329, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01550456

F. J. Harrell, K. Lee, and D. Mark, Multivariable prognostic models: Issues in developing models.; evaluating assumptions and adequacy, and measuring and reducing errors, Stat. Med, vol.5, pp.361-387, 1996.

C. K. Lee, J. Man, S. Lord, W. Cooper, M. Links et al., Clinical and molecular characteristics associated with survival among patients treated with checkpoint inhibitors for advanced non-small cell lung carcinoma: A systematic reviewand meta-analysis, JAMA Oncol, vol.4, pp.210-216, 2018.

D. Rossi and G. Gaidano, Messengers of cell death: Apoptotic signaling in health and disease, Haematologica, vol.88, pp.212-218, 2003.

E. C. Lacasse, D. J. Mahoney, H. H. Cheung, S. Plenchette, S. Baird et al., IAP-targeted therapies for cancer, Oncogene, vol.27, pp.6252-6275, 2008.

A. Philchenkov and K. Miura, The IAP Protein Family, SMAC Mimetics and Cancer Treatment, Crit. Rev. Oncog, vol.21, pp.185-202, 2016.